Article Text

Download PDFPDF
Priority vaccination for mental illness, developmental or intellectual disability
  1. Nina Shevzov-Zebrun1,
  2. Arthur L Caplan2
  1. 1 Grossman School of Medicine, NYU Langone Health, New York, New York, USA
  2. 2 Division of Medical Ethics, Grossman School of Medicine, NYU Langone Health, New York, New York, USA
  1. Correspondence to Nina Shevzov-Zebrun, Grossman School of Medicine, NYU Langone Health, New York, NY 10016-4576, USA; nsz220{at}nyumc.org

Abstract

Coronavirus vaccines have made their debut. Now, allocation practices have stepped into the spotlight. Following Centers for Disease Control and Prevention guidelines, states and healthcare institutions initially prioritised healthcare personnel and elderly residents of congregant facilities; other groups at elevated risk for severe complications are now becoming eligible through locally administered programmes. The question remains, however: who else should be prioritised for immunisation? Here, we call attention to individuals institutionalised with severe mental illnesses and/or developmental or intellectual disabilities—a group highly susceptible to the damages of COVID-19, recent research shows, and critical to consider for priority vaccination. The language describing both federal-level and state-level intentions for this population remains largely vague, despite the population’s diversity across age, diagnosis, functional status and living arrangement. Such absence of specificity, in turn, leaves room for confusion and even neglect of various subgroups. We review data stressing this group’s vulnerability, as well as select state plans for priority vaccination, highlighting the importance of clarity when describing intentions to vaccinate, or even generally care for, diverse populations composed of distinct subgroups in need.

  • COVID-19
  • resource allocation

Data availability statement

All data relevant to the study are included in the article.

This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

https://bmj.com/coronavirus/usage

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

All data relevant to the study are included in the article.

View Full Text

Footnotes

  • Twitter @arthurcaplan

  • Contributors NSZ performed data curation/collection, literature review, and drafting and revising. ALC conceptualised, supervised and critically reviewed/edited the piece, approving it for final publication.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Other content recommended for you